|1.||Papp, Kim A: 17 articles (01/2008 - 12/2003)|
|2.||Menter, Alan: 15 articles (06/2014 - 04/2003)|
|3.||Caro, Ivor: 12 articles (03/2008 - 09/2004)|
|4.||Leonardi, Craig L: 11 articles (01/2008 - 08/2003)|
|5.||Gottlieb, Alice B: 10 articles (07/2006 - 05/2002)|
|6.||Krueger, James G: 9 articles (01/2012 - 05/2002)|
|7.||Gordon, Kenneth B: 9 articles (09/2009 - 12/2003)|
|8.||Weinberg, Jeffrey M: 9 articles (03/2009 - 12/2002)|
|9.||Kwon, Paul: 9 articles (06/2007 - 03/2005)|
|10.||Dummer, Wolfgang: 8 articles (11/2008 - 05/2003)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
06/01/2009 - "Efalizumab is an effective and safe treatment for psoriasis in most patients of a high need population in routine practice, and provides maintained improvement in 'responders'. "
01/01/2009 - "The authors present a case of a patient with severe inverse psoriasis who was successfully treated with efalizumab, resulting in complete and sustained remission during prolonged maintenance therapy."
09/01/2005 - "Efalizumab thus appears as an important option in the long-term management of chronic plaque psoriasis."
01/01/2005 - "In randomized, double-blind, placebo-controlled trials, efalizumab 1.0 mg/kg, administered subcutaneously once weekly for 12 weeks, significantly reduced disease activity in patients with chronic, moderate-to-severe plaque psoriasis. "
01/01/2004 - "Compared to placebo-treated patients, efalizumab-treated patients showed significant improvement in patient-reported outcomes, reducing the limitations and burden associated with moderate to severe psoriasis within each of the three studies, as measured by DLQI (p<0.001), PSA-Severity (p<0.001), PSA-Frequency (p<0.001), and Itch (p<0.001) scores. "
05/01/2008 - "These data suggest that blockade of T-cell extravasation into tissue is the major pathway by which efalizumab leads to improvement in cutaneous inflammation."
10/01/2010 - "Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. "
08/01/2003 - "A randomized, double-blinded, placebo-controlled, parallel group, multicenter study investigated the effects of efalizumab on allergen-induced airway responsiveness and airway inflammation. "
01/01/2006 - "Here, we review the inflammatory pathway that drives the development of psoriasis, and we discuss several mechanisms by which efalizumab suppresses skin inflammation in psoriasis. "
08/01/2003 - "The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma."
03/01/2007 - "Efalizumab for the treatment of psoriatic arthritis."
01/01/2006 - "It can be speculated that a possible mechanism for efalizumab-induced psoriatic arthritis is related to the blockade of regulatory T cells from joint tissue."
01/01/2006 - "Severe exacerbation of psoriatic arthritis during treatment with efalizumab. "
07/01/2005 - "The effectiveness of one of these agents, efalizumab, did not achieve statistical significance in the treatment of psoriatic arthritis. "
09/01/2007 - "Efalizumab is effective for skin psoriasis but not psoriatic arthritis. "
02/01/2010 - "Lymphoma and immunosuppression: a report of a case associated with efalizumab therapy."
06/01/2007 - "There has been mounting evidence that efalizumab may be associated with lymphoma/malignancy development. "
02/01/2010 - "Discontinuation of efalizumab resulted in a partial remission of lymphoma, although administration of chemotherapy was ultimately required. "
03/01/2009 - "Other mAbs such as rituximab, daclizumab, efalizumab, and alemtuzumab showed positive results in animal and early clinical studies and may represent useful adjuvant therapies for ocular lymphoma or ocular inflammation. "
01/01/2005 - "Improvements from baseline on the SF-36, PSA, PGPA, and itching VAS at Week 12 were also significantly greater in efalizumab-treated patients than for placebo. "
12/17/2003 - "Efalizumab-treated patients exhibited significantly greater mean percentage improvement than placebo-treated patients on the overall DLQI (47% vs 14%; P<.001), Itching VAS (38% vs -0.2%; P<.001), and PSA frequency and severity subscales (48% vs 18% and 47% vs 17%, respectively; P<.001 for both) at the first assessment point. "
|1.||TNFR-Fc fusion protein (etanercept)
|5.||Immunoglobulin G (IgG)
|10.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|2.||Phototherapy (Light Therapy)
|4.||Drug Therapy (Chemotherapy)
|5.||Complementary Therapies (Alternative Medicine)